Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized...

Area of Science:

• Endocrinology
• Bone Metabolism
• Cardiovascular Health

Background:

• Osteoporosis and hypercholesterolemia share a documented link.
• Bone resorption inhibitors like nitrogen-containing bisphosphonates (N-BP) and selective estrogen receptor modulators (SERMs) can lower cholesterol.
• The impact of baseline cholesterol on fracture risk with these inhibitors is unclear.

Purpose of the Study:

• To investigate the relationship between baseline cholesterol levels and incident vertebral fractures.
• To compare the efficacy of N-BP (minodronic acid) and SERM (raloxifene) in managing osteoporosis and cholesterol.
• To assess the cholesterol-lowering effects of these treatments in osteoporosis patients.

Main Methods:

• Prospective, randomized, open-label study with 3986 osteoporosis patients.
• Patients were treated with either minodronic acid (MIN) or raloxifene (RLX).
• Serum cholesterol levels and vertebral fracture incidence were monitored over 2 years.

Main Results:

• MIN significantly reduced vertebral fracture rates in patients with baseline LDL cholesterol ≥140 mg/dL, HDL cholesterol <40 mg/dL, age ≥75 years, or low BMD (T-score ≤-3 SD) compared to RLX.
• RLX demonstrated a stronger cholesterol-lowering effect than MIN, irrespective of prior statin use.
• MIN was more effective in fracture risk reduction for patients with higher LDL cholesterol levels.

Conclusions:

• Minodronic acid offers superior vertebral fracture risk reduction in specific osteoporosis patient subgroups with elevated LDL cholesterol compared to raloxifene.
• While raloxifene exhibits a greater cholesterol-lowering capacity, minodronic acid's efficacy in preventing fractures in high-risk individuals is notable.
• Treatment choice for osteoporosis may consider baseline lipid profiles for optimized fracture prevention outcomes.